|Bid||1,370.00 x 0|
|Ask||1,456.00 x 0|
|Day's range||1,379.00 - 1,429.86|
|52-week range||1,280.92 - 2,746.59|
|Beta (5Y monthly)||0.27|
|PE ratio (TTM)||13.45|
|Earnings date||26 Apr 2023|
|Forward dividend & yield||0.61 (4.08%)|
|Ex-dividend date||23 Feb 2023|
|1y target est||N/A|
Roland Head looks at the latest GSK dividend forecasts and explains why he'd consider buying the stock today, despite certain risks. The post Here’s the GSK dividend forecast for 2023 and 2024 appeared first on The Motley Fool UK.
No vaccine has been approved to prevent respiratory syncytial virus (RSV), but there are more than 30 different RSV vaccine candidates in clinical trials, according to PATH, a global health organization. Research from the Centers for Disease Control and Prevention (CDC) estimate that between 60,000 and 160,000 adults 65 and older are hospitalized each year with RSV, and 6,000 to 10,000 older adults die because of it. One to two out of every 100 children younger than 6 months of age with an RSV infection may need to be hospitalized.
If we suffer a stock market crash, some FTSE shares will surely handle it better than others. Finding them is what's tricky. The post 3 crash-resistant FTSE shares to buy today? appeared first on The Motley Fool UK.